Scott Neils Net Worth

The estimated Net Worth of Scott C Neils is at least $257 Thousand dollars as of 18 January 2023. Mr Neils owns over 8,673 units of Xtant Medical Inc stock worth over $248,435 and over the last 3 years he sold XTNT stock worth over $8,348.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Neils XTNT stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Xtant Medical Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 8,673 units of XTNT stock worth $5,291 on 18 January 2023.

The largest trade he's ever made was selling 8,673 units of Xtant Medical Inc stock on 18 January 2023 worth over $5,291. On average, Mr trades about 2,149 units every 22 days since 2022. As of 18 January 2023 he still owns at least 403,960 units of Xtant Medical Inc stock.

You can see the complete history of Mr Neils stock trades at the bottom of the page.

Mr. Scott Neils biography

Scott Neils is the Interim CFO & Controller at Xtant Medical Inc.

How old is Mr Neils?

Mr Neils is 36, he's been the Interim CFO & Controller of Xtant Medical Inc since . There are 8 older and no younger executives at Xtant Medical Inc. The oldest executive at Xtant Medical Holdings Inc is Darrel Holmes, 62, who is the Chief Operating Officer.

What's Mr Neils's mailing address?

Scott's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.

Insiders trading at Xtant Medical Inc

Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed, and Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.

What does Xtant Medical Inc do?

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Complete history of Mr Neils stock trades at Xtant Medical Inc

Xtant Medical Inc executives and stock owners

Xtant Medical Inc executives and other stock owners filed with the SEC include:

• Sean E. Browne,
  Pres, CEO & Director
• Kevin D. Brandt,
  Sr. VP & Chief Commercial Officer
• Darrel Holmes,
  Chief Operating Officer
• Gregory Juda,
  Chief Scientific Officer
• Rich Cockrell,
  IR Contact Officer
• Matthew Rizzo,
  Director
• Jeffrey Peters,
  Director
• Robert McNamara,
  Director
• Michael Eggenberg,
  Director
• John Bakewell,
  Director
• Kevin Brandt,
  Senior Vice President, Chief Commercial Officer
• Greg Jensen,
  Chief Financial Officer, Vice President - Finance
• Sean Browne,
  President, Chief Executive Officer, Director
• Kevin M. O'Dare,
  VP of Sales - Eastern US
• Catherine Lundy,
  VP of HR
• Scott Neils,
  Interim CFO & Controller
• Scott C Neils,
  Chief Financial Officer
• Jonn R. Beeson,
  Director
• Eric Bernard Timko,
  Director
• Kent L Swanson,
  Director
• John Arthur Deedrick,
  Director
• David Louis Kirschman,
  EVP & Chief Scientific Officer
• Daniel S Goldberger,
  Chief Executive Officer
• Rudy A Mazzocchi,
  Director
• Jon M. Wickwire,
  
• David Goodman,
  
• Paul Buckman,
  Director
• Michael A Lopach,
  Director
• Advisors Llc Orbimed,
  Director
• Kathie J. Lenzen,
  Chief Financial Officer
• Carl O'connell,
  Chief Executive Officer
• Michael Mainelli,
  Interim CEO
• Ronald G. Berlin,
  VP & Chief Operations Officer
• Advisors Llc Orbimed Rof Ii...,
  
• Lori D Mitchell Keller,
  Director
• Mark A. Schallenberger,
  Chief Operations Officer
• Stavros G. Vizirgianakis,
  Director